You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 27, 2024

Details for Patent: 9,321,807


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 9,321,807 protect, and when does it expire?

Patent 9,321,807 protects MAVYRET and is included in two NDAs.

Protection for MAVYRET has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has ten patent family members in seven countries.

Summary for Patent: 9,321,807
Title:Crystal forms
Abstract: The present invention features crystalline forms of Compound I. In one embodiment, a crystalline form of Compound I has characteristic peaks in the PXRD pattern as shown in any one of FIGS. 1-4.
Inventor(s): Chen; Shuang (Gurnee, IL), Gates; Bradley D. (Mt. Prospect, IL), Sheikh; Ahmad Y. (Deerfield, IL)
Assignee: AbbVie Inc. (North Chicago, IL)
Application Number:14/731,765
Patent Claim Types:
see list of patent claims
Composition; Compound; Process;
Patent landscape, scope, and claims:

Analyzing the Scope and Claims of United States Patent 9,321,807

Introduction

United States Patent 9,321,807, titled "Crystal forms," is a patent that describes specific crystalline forms of a compound, here referred to as Compound I. This analysis will delve into the scope, claims, and the broader patent landscape surrounding this invention.

Patent Overview

The patent, issued on May 3, 2016, pertains to crystalline forms of Compound I, which are characterized by their powder X-ray diffraction (PXRD) patterns and purity levels[4].

Scope of the Patent

The scope of the patent is narrowly focused on the crystalline forms of Compound I. Here are the key aspects:

Crystalline Forms

The patent describes multiple crystalline forms of Compound I, each identified by specific peaks in the PXRD pattern. These peaks are critical for distinguishing between different crystalline forms and ensuring the purity of the compound. For example, one crystalline form has characteristic peaks at values of two theta (° 2 θ) such as 8.4, 8.9, 11.1, 12.2, 14.5, and others[4].

Purity Levels

The patent specifies that the crystalline forms can be at least 90% pure, preferably at least 95% pure, or more preferably at least 97% pure. This emphasis on purity indicates the importance of maintaining high standards in the production of these crystalline forms[4].

Claims of the Patent

The claims are the heart of any patent, defining the scope of protection granted to the inventor.

Independent Claims

The independent claims typically define the broadest scope of the invention. For example, Claim 1 might describe a crystalline form of Compound I having specific PXRD peaks and a certain level of purity[4].

Dependent Claims

Dependent claims narrow down the scope further by adding additional limitations. These could include specific methods of preparation, additional characteristics of the crystalline form, or specific applications of the compound.

Claim Analysis

To understand the patent landscape, it is crucial to analyze the claims in detail.

Claim Coverage Matrix

A Claim Coverage Matrix, as described in patent analytics, can help in categorizing the patents and claims by scope concepts. This matrix would show which claims actively protect the intellectual property related to Compound I and where gaps or opportunities exist[3].

Scope Concepts

The scope concepts linked to the claims of this patent would include the specific PXRD peaks, purity levels, and any other distinguishing characteristics of the crystalline forms. These concepts help in filtering and searching large numbers of patent claims efficiently[3].

Patent Landscape

Understanding the broader patent landscape is essential for navigating the intellectual property environment.

Related Patents

The Global Dossier service provided by the USPTO allows users to see the patent family for a specific application, including all related applications filed at participating IP Offices. This can help in identifying other patents related to crystalline forms of similar compounds[1].

Prior Art

The Common Citation Document (CCD) application consolidates prior art cited by all participating offices for the family members of a patent application. This tool is useful for visualizing the search results for the same invention produced by several offices on a single page[1].

Practical Applications and Implications

The crystalline forms described in this patent have practical implications in various fields.

Pharmaceutical Industry

High-purity crystalline forms are crucial in the pharmaceutical industry for ensuring the efficacy and safety of drugs. The specific PXRD patterns and purity levels described in this patent could be critical for the development and manufacturing of pharmaceutical products[4].

Research and Development

For researchers and developers, understanding the exact crystalline forms and their properties is essential for advancing knowledge in the field. This patent provides detailed information that can be used to replicate and further study these crystalline forms.

Legal and Regulatory Considerations

Correctly determining inventorship and ensuring that all inventors are listed is a critical legal aspect of patent applications.

Inventorship

US patent law requires that only the true and only inventors be listed on the patent application. Incorrect or incomplete identification of inventors can lead to challenges to the patent's enforceability[5].

Enforcement

A thorough job of invention disclosure, as mentioned in the context of inventorship, is vital to ensure that the patent remains enforceable against any future challenges.

Key Takeaways

  • Crystalline Forms: The patent describes multiple crystalline forms of Compound I, each characterized by specific PXRD peaks and purity levels.
  • Claims Analysis: The claims define the scope of protection, with independent claims providing the broadest scope and dependent claims adding additional limitations.
  • Patent Landscape: Understanding related patents and prior art through tools like Global Dossier and CCD is crucial for navigating the intellectual property environment.
  • Practical Applications: The patent has significant implications for the pharmaceutical industry and research and development.
  • Legal Considerations: Correct inventorship and thorough invention disclosure are essential for maintaining the enforceability of the patent.

FAQs

Q: What is the main subject matter of United States Patent 9,321,807? A: The main subject matter is the crystalline forms of Compound I, characterized by specific PXRD peaks and purity levels.

Q: How can one identify the different crystalline forms described in the patent? A: The different crystalline forms are identified by their characteristic peaks in the PXRD pattern and their purity levels.

Q: What is the significance of the purity levels mentioned in the patent? A: The purity levels (at least 90%, preferably at least 95%, or more preferably at least 97%) are crucial for ensuring the quality and efficacy of the crystalline forms.

Q: How can tools like Global Dossier and CCD help in understanding the patent landscape? A: These tools provide access to related patent applications and prior art, helping users to visualize the global patent landscape for the same invention.

Q: Why is correct inventorship important in patent applications? A: Correct inventorship is essential to ensure that the patent remains enforceable against any future challenges, as incorrect or incomplete identification can lead to legal issues.

Sources

  1. USPTO - Search for patents - USPTO
  2. USA.gov - U.S. Patent and Trademark Office (USPTO) | USAGov
  3. SLWIP - Patent Analytics | Intellectual Property Law
  4. Google Patents - US9321807B2 - Crystal forms - Google Patents
  5. Oregon State University - Determining Inventorship for US Patent Applications[5]

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 9,321,807

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Abbvie MAVYRET glecaprevir; pibrentasvir PELLETS;ORAL 215110-001 Jun 10, 2021 RX Yes Yes ⤷  Subscribe ⤷  Subscribe Y ⤷  Subscribe
Abbvie MAVYRET glecaprevir; pibrentasvir TABLET;ORAL 209394-001 Aug 3, 2017 RX Yes Yes ⤷  Subscribe ⤷  Subscribe Y ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.